

1 ***Klebsiella pneumoniae* mutants resistant to ceftazidime/avibactam plus**  
 2 **aztreonam, imipenem/relebactam, meropenem/vaborbactam and**  
 3 **cefepime/taniborbactam.**

4

5 **Naphat Satapoomin<sup>a</sup>, Punyawee Dulyayangkul<sup>a</sup>, Matthew B. Avison<sup>a#</sup>**

6

7 **<sup>a</sup>School of Cellular & Molecular Medicine, University of Bristol,**  
 8 **Bristol. UK**

9

10 **#Address correspondence to: Matthew B. Avison. [bimba@bris.ac.uk](mailto:bimba@bris.ac.uk)**

11

12

13 **Running Head:  $\beta$ -lactam/ $\beta$ -lactamase inhibitor resistance**

## 14 ABSTRACT

15 Using modified *Klebsiella pneumoniae* clinical isolates, we show that *ramR*  
 16 plus *ompK36* mutation together with production of the V239G variant KPC-3  
 17 confers resistance to ceftazidime/avibactam plus aztreonam,  
 18 imipenem/relebactam and meropenem/vaborbactam, but not  
 19 cefepime/taniborbactam. This is because the V239G variant does not generate  
 20 collateral  $\beta$ -lactam susceptibility as do many other KPC-3 variants associated  
 21 with ceftazidime/avibactam resistance. Additional mutation of *ompK35* and  
 22 carriage of a plasmid expressing the OXA-48-like carbapenemase OXA-232  
 23 was required to confer cefepime/taniborbactam resistance.

24

25

## 26 TEXT

27 Aztreonam/avibactam (AZT/AVI) is a  $\beta$ -lactam/ $\beta$ -lactamase inhibitor combination  
 28 currently in clinical trials, which has activity against Enterobacterales producing  
 29 metallo-carbapenemases and those with aztreonam-hydrolysing enzymes such as  
 30 plasmid-mediated AmpCs (pAmpCs), extended-spectrum  $\beta$ -lactamases (ESBLs) and  
 31 the serine carbapenemase KPC. All these enzymes are increasingly carried in  
 32 *Klebsiella pneumoniae*, and yet few studies have been performed to consider  
 33 mechanisms of AZT/AVI resistance in this species. It was recently reported that  
 34 among 8787 Enterobacterales isolates, 17 were AZT-AVI resistant. Of these, three  
 35 *Klebsiella* spp, were identified. Production of the pAmpC, DHA-1 plus *acrA* efflux  
 36 pump gene overexpression and mutation of *ompK35* or *ompK36* porins were  
 37 identified in two resistant isolates. The other produced the ESBL PER-2 and carried  
 38 an *ompK35* loss of function mutation (1). In one *in vitro* study, selecting AZT/AVI  
 39 resistance identified mutations in the pAmpC, CMY-16 in a *K. pneumoniae* strain (2).  
 40 Avibactam is currently in clinical use partnered by ceftazidime (CAZ/AVI) and here,  
 41 mutations in KPC are known to confer resistance. However, such mutations tend to  
 42 reduce hydrolytic activity to  $\beta$ -lactams other than ceftazidime, including carbapenems  
 43 and aztreonam (3-6). Accordingly, it is conceivable that such mutant KPC enzymes  
 44 might not confer AZT/AVI resistance.

45 Another recently licenced  $\beta$ -lactam/ $\beta$ -lactamase inhibitor combination is  
 46 imipenem/relebactam (IMI/REL). Unlike AZT/AVI, this does not have efficacy against  
 47 isolates producing metallo carbapenemases, but is generally efficacious against  
 48 Enterobacterales producing pAmpC, KPC and ESBLs (7). Again, analysis of clinical

49 isolates shows that IMI/REL resistance in *K. pneumoniae* is rare, but resistant  
 50 isolates have mutations in or reduced expression of *ompK35* and/or *ompK36* porin  
 51 genes and/or increased *acrA* efflux pump gene expression, alongside ESBL  
 52 production (8). Similar impacts of porin and efflux pump production on IMI/REL  
 53 susceptibility have been seen in *in vitro* studies using KPC-producing isolates (9).

54 Given seeming overlaps between AZT/AVI and IMI/REL resistance mechanisms in  
 55 *K. pneumoniae*, we set out to dissect the mechanisms contributing to resistance to  
 56 each in *K. pneumoniae* using a bank of clinical isolates and targeted recombinants  
 57 having fully defined genotypes. **Table 1** reports MICs (determined using CLSI broth  
 58 microdilution methodology [10,11]) of these combinations against a collection of  
 59 clinical isolates, which have been previously described (12) and their  $\beta$ -lactam  
 60 resistance genotypes characterised (13). All isolates, whether producing  
 61 carbapenemases of classes A (KPC-3), B (NDM-1) or D (OXA-232) were AZT/AVI  
 62 susceptible, but the NDM-1/OXA-232 producer KP4 was, as expected IMI/REL  
 63 resistant, as was the OXA-232 producer KP11, though with lower MICs (**Table 1**).  
 64 Notably, KP4 and KP11 have *ramR* mutations (12), which leads to over production of  
 65 AcrAB-TolC efflux pump, and reduced production of the OmpK35 porin in *K.*  
 66 *pneumoniae* (14). Nonetheless, a *ramR* mutant clinical isolate producing KPC-3,  
 67 KP30, was susceptible to both AZT/AVI and IMI/REL (**Table 1**) so we conclude that  
 68 modulating production of these permeability-associated proteins is not sufficient to  
 69 give resistance to either  $\beta$ -lactam/ $\beta$ -lactamase inhibitor combination in a KPC-3  
 70 positive background.

71 To investigate the role of *bla*<sub>KPC-3</sub> mutations known to be associated with CAZ/AVI  
 72 resistance (15) in AZT/AVI and IMI/REL susceptibility, we took clinical *K.*  
 73 *pneumoniae* isolate KP21, which is a *ramR* mutant and fully susceptible to AZT and  
 74 IMI (**Table 1**). We introduced *bla*<sub>KPC-3</sub> on a plasmid (pKPC-3), either wild-type or  
 75 following site-directed mutagenesis to create a D178Y or V239G mutations  
 76 (numbering based on the original KPC-3 sequence nomenclature [16]), previously  
 77 associated with CAZ/AVI resistance (15). The construction of these plasmids has  
 78 been reported previously (17). Reduced MICs of AZT and IMI were observed against  
 79 KP21 carrying the D178Y variant, compared with KP21 carrying wild-type KPC-3  
 80 (**Table 2**). This phenomenon of reduced spectrum of  $\beta$ -lactamase activity has been  
 81 described for other *bla*<sub>KPC-3</sub> mutants associated with CAZ/AVI resistance (3-6).  
 82 However, in a KP21 background, this reduction in activity was seen to a greater  
 83 extent for the D178Y mutant, than the V239G variant (**Table 2**). This observation fits  
 84 with previous reports that *K. pneumoniae* carrying the V239G mutant *bla*<sub>KPC-3</sub> remain  
 85 meropenem resistant, while those carrying the D178Y mutant are meropenem  
 86 susceptible (15, 17). However, AZT/AVI and IMI/REL MICs were not greatly elevated  
 87 against KP21 carrying pKPC-3 V239G in comparison with KP21 carrying pKPC-3,  
 88 and all these KP21 recombinants remained AZT/AVI and IMI/REL susceptible (**Table**  
 89 **2**). We conclude, therefore, that mutating *bla*<sub>KPC-3</sub> in a way that gives CAZ/AVI  
 90 resistance is not sufficient to give AZT/AVI or IMI/REL resistance, even in a *ramR*  
 91 mutant *K. pneumoniae* background.

92 Addition of an OXA-232 (class D carbapenemase) plasmid (pOXA-232, as described  
 93 in our previous work [17]) to the KP21 recombinant carrying pKPC-3 V239G  
 94 conferred IMI/REL (but not AZT/AVI) resistance, but this was not seen for KP21

recombinants carrying pKPC-3 D178Y or pKPC-3 (**Table 2**). Disruption of the *ompK36* porin gene in KP21 (as described previously[17]) conferred AZT/AVI and IMI/REL resistance when the recombinant was carrying pKPC-3 V239G, but not when it carried pKPC-3 D178Y or pKPC-3. Addition of pOXA-232 to the KP21 *ompK36* recombinants further raised MICs against the pKPC-3 V239G recombinant, and actually conferred IMI/REL resistance in the recombinant carrying pKPC-3, but not pKPC-3 D178Y (**Table 2**). Using the *ramR* wild-type isolate KP47 engineered to have an *ompK36* mutation we confirmed that *ramR* mutation is essential for the AZT/AVI resistance seen in KP21 *ompK36* pKPC-3 V239G, even following addition of pOXA-232 (**Table 2**).

We therefore conclude that three steps: mutation of *ramR*, mutation of *ompK36* and carriage of the V239G variant of *bla*<sub>KPC-3</sub> is sufficient for *K. pneumoniae* to become resistant to both AZT/AVI and IMI/REL. However, prior to clinical approval of AZT/AVI, this combination is usually created clinically by adding AZT to CAZ/AVI therapy. A checkerboard assay confirmed that AZT/AVI and IMI/REL resistant derivative KP21[*ramR*] *ompK36* pKPC-3 V239G is also resistant to CAZ/AVI plus AZT, with MICs of CAZ (>32 µg.ml<sup>-1</sup>) and AZT (16 µg.ml<sup>-1</sup>) against this recombinant (**Figure 1**).

We have previously shown that this combination of *ramR* and *ompK36* mutation coupled with acquisition of pKPC-3 V239G also gives resistance to another licenced β-lactam/β-lactamase inhibitor combination meropenem/vaborbactam (17). Finally, therefore, we considered the MIC of another combination in late stage clinical trials, cefepime/taniborbactam (18) against this derivative. Notably, in this *ramR ompK36*

mutant background pKPC-3 D178Y supported lower cefepime MICs than pKPC-3 (Table 3), as seen for the other  $\beta$ -lactams (Table 2) and this was also true for cefepime/taniborbactam (Table 3). But again, the V239G mutant did not suffer from this reduction in cefepime MIC, and the MIC of cefepime/taniborbactam was the same against pKPC-3 and pKPC-3 V239G recombinants of KP21[*ramR*] *ompK36*, being 8  $\mu\text{g}.\text{ml}^{-1}$ , which is one doubling dilution below the cefepime resistance breakpoint (11) (Table 3). Further addition of pOXA-232 elevated cefepime MICs against the recombinants (Table 3), as expected since OXA enzymes are known to hydrolyse cefepime (19), but the cefepime/taniborbactam MIC remained at  $\leq 8 \mu\text{g}.\text{ml}^{-1}$  indicating successful inhibition of OXA-232. However, additional insertional inactivation of *ompK35* porin gene (performed as described previously [17]) pushed the cefepime/taniborbactam MIC against KP21[*ramR*] *ompK36* recombinants carrying pOXA-232 and pKPC-3 V239G (but not pKPC-3 D178Y) to 16  $\mu\text{g}.\text{ml}^{-1}$ , which is classed as cefepime resistant (Table 3).

We conclude, therefore, that whilst three events (*ramR*, *ompK36*, *bla*<sub>KPC-3</sub> V239G) are sufficient to cause AZT/AVI, CAZ/AVI/AZT, IMI/REL and meropenem/vaborbactam resistance in *K. pneumoniae*, additional events are required to give cefepime/taniborbactam resistance. Furthermore, whilst many *bla*<sub>KPC-3</sub> mutations leading to CAZ/AVI resistance do come with the collateral effect of increased susceptibility to carbapenems, late generation cephalosporins and AZT, KPC-3 V239G does not suffer from this effect to the same degree. This explains why KPC-3 V239G, rather than KPC-3 D178Y, which does suffer from collateral increased susceptibility is able to confer resistance to multiple  $\beta$ -lactam/ $\beta$ -lactamase inhibitor combinations, provided their accumulation is slowed. The implication here is

that KPC-3 V239G is inhibited to a lesser extent than KPC-3, rather than having a more ceftazidime focussed hydrolytic spectrum, as does KPC-3 D178Y (20). Accordingly, the emergence of this *bla*<sub>KPC-3</sub> variant should be watched with caution.

## **Funding**

This work was funded by grant MR/S004769/1 to M.B.A. from the Antimicrobial Resistance Cross Council Initiative supported by the seven United Kingdom research councils and the National Institute for Health Research. N.S. received a postgraduate scholarship from the University of Bristol.

## **Transparency declaration**

The authors declare no conflict of interests.


## Figure Legend

### **Figure 1. Checkerboard assays for CAZ and AZT in the presence of AVI against *K. pneumoniae* KP21[ramR] ompK36 producing KPC-3 V239G.**

The image represents duplicate assays for an 8×8 array of wells in a 96-well plate. All wells contained CA-MHB including avibactam (4 µg.ml<sup>-1</sup>). A serial dilution of aztreonam (AZT, x-axis) and ceftazidime (CAZ, y-axis) was created from 32 µg.ml<sup>-1</sup> in each plate as recorded. All wells were inoculated with a suspension of bacteria, made as per CLSI microtiter MIC guidelines (10), and the plate was incubated at 37°C for 20 h. Growth was recorded by measuring OD<sub>600</sub> and growth above background (broth) is recorded as a yellow block; no growth is recorded as a white block. Growth in the red edged block indicates resistance to both AZT and CAZ.

166 **Figure 1**

167



168

**Table 1** MICs of aztreonam and imipenem with or without avibactam or relebactam against *K. pneumoniae* clinical isolates

| Isolate (relevant genotype)                     | MIC ( $\mu\text{g.ml}^{-1}$ ) |            |            |            |
|-------------------------------------------------|-------------------------------|------------|------------|------------|
|                                                 | AZT                           | AZT/AVI    | IMI        | IMI/REL    |
| KP31 (wild-type)                                | $\leq 0.5$                    | $\leq 0.5$ | $\leq 0.5$ | $\leq 0.5$ |
| KP21 ( <i>ramR</i> TEM-1)                       | $\leq 0.5$                    | $\leq 0.5$ | $\leq 0.5$ | $\leq 0.5$ |
| KP11 ( <i>ramR</i> OXA-232 CTX-M-15 TEM-1)      | >128                          | $\leq 0.5$ | 4          | 4          |
| KP30 ( <i>ramR ompK35</i> KPC-3 TEM-1)          | >128                          | 1          | >128       | 1          |
| KP4 ( <i>ramR</i> NDM-1 OXA-232 CTX-M-15 TEM-1) | >128                          | $\leq 0.5$ | 64         | 16         |

Shading indicates resistance based on CLSI breakpoints (11)

**Table 2** MICs of aztreonam or imipenem with or without avibactam or relebactam against derivatives of *K. pneumoniae* clinical isolates KP21 and KP47

| Isolate                                 | MIC ( $\mu\text{g.ml}^{-1}$ ) |            |      |            |
|-----------------------------------------|-------------------------------|------------|------|------------|
|                                         | AZT                           | AZT/AVI    | IMI  | IMI/REL    |
| KP21[ramR] pUBYT                        | 0.5                           | $\leq 0.5$ | 0.5  | $\leq 0.5$ |
| KP21[ramR] pKPC-3                       | >128                          | 1          | 64   | 2          |
| KP21[ramR] pKPC-3 D178Y                 | 1                             | $\leq 0.5$ | 1    | 0.5        |
| KP21[ramR] pKPC-3 V239G                 | >128                          | 2          | 32   | 2          |
| KP21[ramR] pUBYT pOXA-232               | 0.5                           | $\leq 0.5$ | 2    | 1          |
| KP21[ramR] pKPC-3 pOXA-232              | >128                          | 2          | 128  | 2          |
| KP21[ramR] pKPC-3 D178Y pOXA-232        | 16                            | 2          | 2    | 2          |
| KP21[ramR] pKPC-3 V239G pOXA-232        | >128                          | 4          | 32   | 8          |
| KP21[ramR] ompK36 pUBYT                 | 0.5                           | 1          | 2    | 0.5        |
| KP21[ramR] ompK36 pKPC-3                | >128                          | 2          | 128  | 2          |
| KP21[ramR] ompK36 pKPC-3 D178Y          | 8                             | 2          | 1    | 0.5        |
| KP21[ramR] ompK36 pKPC-3 V239G          | >128                          | 16         | 128  | 4          |
| KP21[ramR] ompK36 pUBYT pOXA-232        | 1                             | 1          | 4    | 2          |
| KP21[ramR] ompK36 pKPC-3 pOXA-232       | >128                          | 2          | >128 | 32         |
| KP21[ramR] ompK36 pKPC-3 D178Y pOXA-232 | 8                             | 4          | 8    | 2          |
| KP21[ramR] ompK36 pKPC-3 V239G pOXA-232 | >128                          | 16         | >128 | 32         |
| KP47 ompK36 pUBYT                       | 0.5                           | $\leq 0.5$ | 0.5  | 0.5        |
| KP47 ompK36 pKPC-3                      | >128                          | 1          | >128 | 8          |
| KP47 ompK36 pKPC-3 D178Y                | 16                            | 2          | 1    | 0.5        |
| KP47 ompK36 pKPC-3 V239G                | >128                          | 4          | >128 | 16         |
| KP47 ompK36 pUBYT pOXA-232              | 0.5                           | $\leq 0.5$ | 2    | 1          |
| KP47 ompK36 pKPC-3 pOXA-232             | >128                          | 1          | >128 | 8          |
| KP47 ompK36 pKPC-3 D178Y pOXA-232       | 16                            | 2          | 4    | 2          |
| KP47 ompK36 pKPC-3 V239G pOXA-232       | >128                          | 4          | >128 | 16         |

Shading indicates resistance based on CLSI breakpoints (11)

**Table 3** MICs of cefepime/taniborbactam against derivatives of *K. pneumoniae*

clinical isolate KP21

| Isolate                                                        | MIC ( $\mu\text{g.ml}^{-1}$ ) |                            |
|----------------------------------------------------------------|-------------------------------|----------------------------|
|                                                                | Cefepime                      | Cefepime/<br>Taniborbactam |
| KP21[ <i>ramR</i> ] <i>ompK36</i> pUBYT                        | 8                             | 1                          |
| KP21[ <i>ramR</i> ] <i>ompK36</i> pKPC-3                       | >256                          | 8                          |
| KP21[ <i>ramR</i> ] <i>ompK36</i> pKPC-3 D178Y                 | 16                            | 2                          |
| KP21[ <i>ramR</i> ] <i>ompK36</i> pKPC-3 V239G                 | >256                          | 8                          |
| KP21[ <i>ramR</i> ] <i>ompK36</i> pUBYT pOXA-232               | 8                             | 1                          |
| KP21[ <i>ramR</i> ] <i>ompK36</i> pKPC-3 pOXA-232              | >256                          | 8                          |
| KP21[ <i>ramR</i> ] <i>ompK36</i> pKPC-3 D178Y pOXA-232        | 64                            | 1                          |
| KP21[ <i>ramR</i> ] <i>ompK36</i> pKPC-3 V239G pOXA-232        | >256                          | 8                          |
| KP21[ <i>ramR</i> ] <i>ompK36 ompK35</i> pUBYT                 | 8                             | 1                          |
| KP21[ <i>ramR</i> ] <i>ompK36 ompK35</i> pKPC-3                | >256                          | 8                          |
| KP21[ <i>ramR</i> ] <i>ompK36 ompK35</i> pKPC-3 D178Y          | 16                            | 2                          |
| KP21[ <i>ramR</i> ] <i>ompK36 ompK35</i> pKPC-3 V239G          | >256                          | 8                          |
| KP21[ <i>ramR</i> ] <i>ompK36 ompK35</i> pUBYT pOXA-232        | 8                             | 2                          |
| KP21[ <i>ramR</i> ] <i>ompK36 ompK35</i> pKPC-3 pOXA-232       | >256                          | 8                          |
| KP21[ <i>ramR</i> ] <i>ompK36 ompK35</i> pKPC-3 D178Y pOXA-232 | 64                            | 2                          |
| KP21[ <i>ramR</i> ] <i>ompK36 ompK35</i> pKPC-3 V239G pOXA-232 | >256                          | 16                         |

## References

1. Mendes RE, Doyle TB, Streit JM, Arhin FF, Sader HS, Castanheira M. 2021. Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019. J Antimicrob Chemother. doi: 10.1093/jac/dkab279. Epub ahead of print.
2. Niu S, Wei J, Zou C, Chavda KD, Lv J, Zhang H, Du H, Tang YW, Pitout JDD, Bonomo RA, Kreiswirth BN, Chen L. 2020. *In vitro* selection of aztreonam/avibactam resistance in dual-carbapenemase-producing *Klebsiella pneumoniae*. J Antimicrob Chemother. 75:559-565.
3. Poirel L, Vuillemin X, Juhas M, Masseron A, Bechtel-Grosch U, Tiziani S, Mancini S, Nordmann P. 2020. KPC-50 Confers Resistance to Ceftazidime-Avibactam Associated with Reduced Carbapenemase Activity. Antimicrob Agents Chemother. 64:e00321-20.
4. Hobson CA, Bonacorsi S, Jacquier H, Choudhury A, Magnan M, Cointe A, Bercot B, Tenaillon O, Birgy A. 2020. KPC Beta-Lactamases Are Permissive to Insertions and Deletions Conferring Substrate Spectrum Modifications and Resistance to Ceftazidime-Avibactam. Antimicrob Agents Chemother. 64:e01175-20.
5. Qin J, Feng Y, Lü X, Zong Z. 2021. KPC-12 with a L169M substitution in the  $\Omega$  loop has reduced carbapenemase activity. Eur J Clin Microbiol Infect Dis. 40:1761-1766.

- 203 6. Findlay J, Poirel L, Juhas M, Nordmann P. 2021. KPC-Mediated Resistance to  
204 Ceftazidime-Avibactam and Collateral Effects in *Klebsiella pneumoniae*.  
205 Antimicrob Agents Chemother. 2021 65:e0089021.
- 206 7. Bush K, Bradford PA. 2019. Interplay between  $\beta$ -lactamases and new  $\beta$ -  
207 lactamase inhibitors. Nat Rev Microbiol. 17:295-306.
- 208 8. Castanheira M, Doyle TB, Deshpande LM, Mendes RE, Sader HS. 2021. Activity  
209 of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam  
210 against carbapenemase-negative carbapenem-resistant Enterobacterales  
211 isolates from US hospitals. Int J Antimicrob Agents. doi:  
212 10.1016/j.ijantimicag.2021.106439. Epub ahead of print.
- 213 9. Balabanian G, Rose M, Manning N, Landman D, Quale J. 2018. Effect of Porins  
214 and blaKPC Expression on Activity of Imipenem with Relebactam in *Klebsiella*  
215 *pneumoniae*: Can Antibiotic Combinations Overcome Resistance? Microb Drug  
216 Resist. 24:877-881.
- 217 10. Clinical and Laboratory Standards Institute. 2015. M07-A10. Methods for dilution  
218 antimicrobial susceptibility tests for bacteria that grow aerobically; approved  
219 standard, 10th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
- 220 11. Clinical and Laboratory Standards Institute. 2021. M100-S31. Performance  
221 standards for antimicrobial susceptibility testing; thirtieth informational  
222 supplement. An informational supplement for global application developed  
223 through the Clinical and Laboratory Standards Institute consensus process.  
224 Clinical and Laboratory Standards Institute, Wayne, PA.
- 225 12. Wan Nur Ismah WAK, Takebayashi Y, Findlay J, Heesom KJ, Jiménez-  
226 Castellanos JC, Zhang J, Graham L, Bowker K, Williams OM, MacGowan AP,  
227 Avison MB. 2018. Prediction of Fluoroquinolone Susceptibility Directly from

228 Whole-Genome Sequence Data by Using Liquid Chromatography-Tandem Mass  
229 Spectrometry To Identify Mutant Genotypes. Antimicrob Agents Chemother.  
230 62:e01814-17.

231 13. Takebayashi Y, Wan Nur Ismah WAK, Findlay J, Heesom KJ, Zhang J, Williams  
232 OM, MacGowan AP, Avison MB. 2017. Prediction of cephalosporin and  
233 carbapenem susceptibility in multi-drug resistant Gram-negative bacteria using  
234 liquid chromatography-tandem mass spectrometry. BioRxiv  
235 <https://doi.org/10.1101/138594>.

236 14. Jiménez-Castellanos JC, Wan Nur Ismah WAK, Takebayashi Y, Findlay J,  
237 Schneiders T, Heesom KJ, Avison MB. 2018. Envelope proteome changes driven  
238 by RamA overproduction in *Klebsiella pneumoniae* that enhance acquired  $\beta$ -  
239 lactam resistance. J Antimicrob Chemother 73:88-94.

240 15. Shields RK, Chen L, Cheng S, Chavda KD, Press EG, Snyder A, Pandey R, Doi  
241 Y, Kreiswirth BN, Nguyen MH, Clancy CJ. 2017. Emergence of ceftazidime-  
242 avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment  
243 of carbapenem-resistant *Klebsiella pneumoniae* infections. Antimicrob Agents  
244 Chemother 61:e02097-16.

245 16. Woodford N, Tierno PM Jr, Young K, Tysall L, Palepou MF, Ward E, Painter RE,  
246 Suber DF, Shungu D, Silver LL, Inglima K, Kornblum J, Livermore DM. 2004.  
247 Outbreak of *Klebsiella pneumoniae* producing a new carbapenem-hydrolyzing  
248 class A  $\beta$ -lactamase, KPC-3, in a New York Medical Center. Antimicrob Agents  
249 Chemother 48:4793-4799.

250 17. Dulyayangkul P, Douglas EJA, Lastovka F, Avison MB. 2020. Resistance to  
251 Ceftazidime/Avibactam plus Meropenem/Vaborbactam When Both Are Used

- 252        Together Is Achieved in Four Steps in Metallo- $\beta$ -Lactamase-Negative *Klebsiella*  
253        pneumoniae. *Antimicrob Agents Chemother.* 64:e00409-20.
- 254    18. Hamrick JC, Docquier JD, Uehara T, Myers CL, Six DA, Chatwin CL, John KJ,  
255        Vernacchio SF, Cusick SM, Trout REL, Pozzi C, De Luca F, Benvenuti M,  
256        Mangani S, Liu B, Jackson RW, Moeck G, Xerri L, Burns CJ, Pevear DC, Daigle  
257        DM. 2020. VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine-  
258        and Metallo- $\beta$ -Lactamases, Restores Activity of Cefepime in Enterobacterales  
259        and *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother.* 64:e01963-19.
- 260    19. Torres E, López-Cerero L, Rodríguez-Martínez JM, Pascual Á. 2016. Reduced  
261        Susceptibility to Cefepime in Clinical Isolates of Enterobacteriaceae Producing  
262        OXA-1 Beta-Lactamase. *Microb Drug Resist.* 22:141-6.
- 263    20. Compain F, Arthur M. 2017. Impaired Inhibition by Avibactam and Resistance to  
264        the Ceftazidime-Avibactam Combination Due to the D179Y Substitution in the  
265        KPC-2  $\beta$ -Lactamase. *Antimicrob Agents Chemother.* 61:e00451-17.